United Therapeutics (NASDAQ:UTHR) Coverage Initiated by Analysts at StockNews.com

Posted by Defense World Staff on Oct 6th, 2023

Stock analysts at StockNews.com started coverage on shares of United Therapeutics (NASDAQ:UTHR – Get Free Report) in a report released on Thursday. The firm set a “buy” rating on the biotechnology company’s stock.

Other equities research analysts have also issued research reports about the stock. LADENBURG THALM/SH SH boosted their price target on shares of United Therapeutics from $256.00 to $268.00 and gave the company a “buy” rating in a report on Thursday, August 3rd. HC Wainwright reiterated a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a report on Thursday, August 3rd. Morgan Stanley lifted their price target on United Therapeutics from $316.00 to $318.00 and gave the company an “overweight” rating in a report on Thursday, August 3rd. Finally, Wedbush lifted their price objective on shares of United Therapeutics from $305.00 to $307.00 and gave the company an “outperform” rating in a research note on Thursday, August 3rd. One analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $296.44.

Check Out Our Latest Stock Report on United Therapeutics

United Therapeutics Stock Up 2.9 %

UTHR stock opened at $228.29 on Thursday. The firm’s 50-day simple moving average is $228.90 and its 200 day simple moving average is $225.33. The stock has a market cap of $10.71 billion, a PE ratio of 12.91 and a beta of 0.61. The company has a quick ratio of 8.40, a current ratio of 8.68 and a debt-to-equity ratio of 0.15. United Therapeutics has a fifty-two week low of $204.44 and a fifty-two week high of $283.09.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported $5.24 EPS for the quarter, beating analysts’ consensus estimates of $4.57 by $0.67. The business had revenue of $596.50 million for the quarter, compared to analyst estimates of $524.18 million. United Therapeutics had a net margin of 41.29% and a return on equity of 17.52%. The business’s revenue for the quarter was up 27.8% on a year-over-year basis. During the same quarter last year, the business earned $2.41 earnings per share. As a group, sell-side analysts predict that United Therapeutics will post 18.95 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Paul A. Mahon sold 6,000 shares of the business’s stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $236.25, for a total value of $1,417,500.00. Following the completion of the transaction, the executive vice president now owns 36,599 shares in the company, valued at approximately $8,646,513.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of the business’s stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $236.25, for a total transaction of $1,417,500.00. Following the completion of the sale, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at approximately $8,646,513.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Paul A. Mahon sold 2,500 shares of the stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $243.87, for a total transaction of $609,675.00. Following the completion of the transaction, the executive vice president now owns 36,599 shares in the company, valued at $8,925,398.13. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 20,883 shares of company stock valued at $4,783,359. 12.50% of the stock is currently owned by corporate insiders.

Institutional Trading of United Therapeutics

Several hedge funds have recently bought and sold shares of UTHR. Massmutual Trust Co. FSB ADV grew its stake in shares of United Therapeutics by 61.4% during the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 163 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 62 shares in the last quarter. Machina Capital S.A.S. acquired a new position in United Therapeutics in the 1st quarter valued at about $45,000. Neo Ivy Capital Management bought a new position in United Therapeutics in the 2nd quarter valued at about $48,000. Global Retirement Partners LLC increased its stake in shares of United Therapeutics by 198.7% during the first quarter. Global Retirement Partners LLC now owns 224 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 149 shares during the period. Finally, Atlas Capital Advisors LLC bought a new position in United Therapeutics during the 4th quarter worth $51,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

About United Therapeutics

(Get Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.